更多栏目
搜索
ADCs and Immuno-Oncology Therapies Attract Massive Investments
储旻华·3月以前
PharmaDJ

Writer: Minhua Chu, Long Cheng

Editor: Justin Fischer


May's tally of fundraising deals for drug developers in China remains on par with that of April, but there has been a remarkable spike in the total dollar value.  Of 23 venture capital investement deals, 21 were publicly disclosed, reaching a total value of $957 million.



Antibody-drug conjugates (ADCs) are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. In recent years, ADCs have become one of the hottest classes in China’s drug development with two HER2-targeted ADCs already green lighted by the NMPA.


Three biopharmacetical companies focusing on ADCs secured considerable investment from venture capitals firms. Among them, DAC  Biotech received $156 million in Series C funding, the largest investment of the month.


The investment was co-led by PE firm Hillhouse Capital’s venture unit GL Ventures, Hong Kong-based healthcare investment firm CDG Capital, and state-backed CITIC Private Equity Funds Management (CPE).


Since its inception in 2012, DAC has specialized in developing ADCs and small molecular cytotoxic anti-tumor drugs. Its lead candidates, DAC-002 (targeted Trop2) and DX126-262 (targeted HER2), have now entered Phase I clincial trials in China.


Two other ADCs developers, Duality Biologics and GeneQuantum Healthcare, also recevied investments this month valued at $90 million and $10 million, respectively.


Immuno-oncology therapies are another class in high demand with investors. Elpiscience Biopharma, a Shanghai-based clincial stage innovative immuno-oncology drug developer, received $105 million in Series C funding. The investment was led by the Greater Bay Area Homeland Development Fund, a state-backed industry fund launched in 2018 to support high-tech industries in the Guangdong-Hong Kong-Macau Greater Bay Area.


Now, Elpiscience Biopharma has pipelines with 15 experimental drugs. Three are in early-stage clincial development.


Source: Elpiscience Biopharma

(https://www.elpiscience.com/cn/index.php?c=article&a=type&tid=416)


gaitubao_WechatIMG5209.png



文章关键字: ADCs Elpiscience GeneQuantum Healthcare HER2 DAC Biotech Duality Biologics Immuno-Oncology Therapies Antibody-drug conjugates
539
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明